Opiant Pharmaceuticals (OPNT) News Today → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free OPNT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineHikma Pharmaceuticals PLC ADR (HKMPY)investing.com - April 18 at 12:44 AMIonis Pharmaceuticalsforbes.com - January 31 at 7:06 AMUPDATE 2-US FDA approves Opiant's spray for reversing opioid-related overdosesmsn.com - May 24 at 10:52 AMREFILE-US FDA approves Opiant's overdose reversal spraymsn.com - May 23 at 8:46 AMIndivior Acquires Opiant Pharmaceuticals Strengthening Its Addiction Treatment And Science Portfoliomsn.com - March 3 at 5:24 PMmarketbeat.com - March 2 at 6:00 AMOpiant Pharmaceuticals, Inc.'s (NASDAQ:OPNT) largest shareholders are individual investors with 52% ownership, institutions own 33%finance.yahoo.com - February 22 at 10:44 AMOpiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLCfinance.yahoo.com - February 7 at 8:53 PMHorizon Pharma, Opiant fall amid Elizabeth Warren concern about pharma deals (update)seekingalpha.com - January 26 at 7:17 PMOpiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdosefinance.yahoo.com - January 19 at 8:13 PMDechra Pharmaceuticals defies cooling pets marketthetimes.co.uk - January 14 at 8:18 PMOpiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown Inseekingalpha.com - January 13 at 6:24 PMOpiant Pharmaceuticals, Inc. (NASDAQ:OPNT) CEO Sells $23,896.60 in Stockmarketbeat.com - January 9 at 6:33 PMOPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant ...businesswire.com - January 7 at 6:45 PMOpiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Short Interest Updatemarketbeat.com - December 28 at 7:44 PMOpiant Pharmaceuticals (NASDAQ:OPNT) Cut to "Market Perform" at Northland Securitiesmarketbeat.com - November 23 at 8:29 AMOpiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdosefinance.yahoo.com - November 22 at 4:08 PMOppenheimer Comments on Opiant Pharmaceuticals, Inc.'s FY2022 Earnings (NASDAQ:OPNT)marketbeat.com - November 17 at 7:52 AMOPNT Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of Opiant Pharmaceuticalsbenzinga.com - November 15 at 6:58 AMEQUITY ALERT: The M&A Class Action Firm Announces the Investigation of Opiant Pharmaceuticals, Inc. - OPNTbenzinga.com - November 15 at 6:58 AMShareholder Alert: Ademi LLP investigates whether Opiant Pharmaceuticals Inc. has obtained a Fair Price in its transaction with Indiviorbenzinga.com - November 14 at 12:18 PMOPNT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Opiant Pharmaceuticals, Inc. Is Fair to Shareholdersbenzinga.com - November 14 at 12:18 PMIndivior To Buy Opiant For $145 Mln In Cashnasdaq.com - November 14 at 7:17 AMOpiant surges 123% as Indivior set to acquire overdose therapy maker for $145Mseekingalpha.com - November 14 at 7:17 AMOpiant Pharmaceuticals Shares Surge Premarket on Takeover by Indivior >OPNTmarketwatch.com - November 14 at 7:17 AMIndivior PLC to Acquire Opiant Pharmaceuticalsfinance.yahoo.com - November 14 at 7:17 AMOpiant Pharmaceuticals Announces Third Quarter 2022 Financial Resultsfinance.yahoo.com - November 14 at 7:17 AMNarcan Owner Opiant to Be Acquired by Indivior for $145 Millionfinance.yahoo.com - November 14 at 2:17 AMThe past five years for Opiant Pharmaceuticals (NASDAQ:OPNT) investors has not been profitablefinance.yahoo.com - November 2 at 11:16 AMOpiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022finance.yahoo.com - October 27 at 7:32 PMOpiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use Disorderfinance.yahoo.com - October 6 at 1:23 PMINVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Opiant Pharmaceuticals, Inc. for Potential Breach of Fiduciary Duty Claimsmarketwatch.com - October 5 at 12:00 PMOpiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis Syndromefinance.yahoo.com - August 22 at 5:33 PMAnalysts Just Shaved Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts Dramaticallyfinance.yahoo.com - August 13 at 9:16 AMOpiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Updatefinance.yahoo.com - August 11 at 4:27 PMOpiant Pharma Secures Additional BARDA Funding For Opioid Overdose Treatmentfinance.yahoo.com - August 9 at 12:09 PMOpiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal Nalmefenefinance.yahoo.com - August 8 at 8:53 PMOpiant Pharmaceuticals, Inc. (NASDAQ:OPNT) insiders sold US$871k worth of stock, possibly signalling a downtrendnasdaq.com - August 4 at 2:16 PMOpiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent With Claims Covering OPNT003 for the Treatment of Opioid Overdosefinance.yahoo.com - August 2 at 8:58 PMOpiant Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022finance.yahoo.com - August 1 at 8:17 PMA Look At The Fair Value Of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)finance.yahoo.com - June 9 at 11:58 AMOpiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal Nalmefenefinance.yahoo.com - June 8 at 8:56 PMOpiant Pharmaceuticals Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdosefinance.yahoo.com - June 1 at 9:05 PMOpiant Pharmaceuticals to Hold Virtual 2022 Annual Shareholder Meeting on Tuesday, June 14, 2022 at 9:00am PDTfinance.yahoo.com - May 20 at 8:38 PMOpiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q1 2022 Results - Earnings Call Transcriptseekingalpha.com - May 14 at 10:14 PMmarketbeat.com - May 13 at 9:40 AMmarketbeat.com - May 13 at 9:32 AMOPNT: Positive Results for Pharmacodynamic Trial of OPNT003…finance.yahoo.com - May 12 at 1:46 PMmarketbeat.com - May 11 at 1:03 PMOpiant Pharmaceuticals Posts Wider Q1 Lossca.investing.com - May 10 at 7:23 PM Get Opiant Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OPNT and its competitors with MarketBeat's FREE daily newsletter. Email Address Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow. Click here for your free guide OPNT Media Mentions By Week OPNT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OPNT News Sentiment▼0.000.34▲Average Medical News Sentiment OPNT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OPNT Articles This Week▼00▲OPNT Articles Average Week Get Opiant Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OPNT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: OptiNose News Cartesian Therapeutics News Immunic News FibroGen News Eliem Therapeutics News CytomX Therapeutics News Seres Therapeutics News Rezolute News Clearside Biomedical News Societal CDMO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OPNT) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupTrump is sounding the alarmPreserve GoldHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opiant Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
